|
1
|
Park JR, Bagatell R, London WB, Maris JM,
Cohn SL, Mattay KK and Hogarty M: COG Neuroblastoma Committee:
Children's Oncology Group's 2013 blueprint for research:
Neuroblastoma. Pediatr Blood Cancer. 60:985–993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Irwin MS and Park JR: Neuroblastoma:
Paradigm for precision medicine. Pediatr Clin North Am. 62:225–256.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tong JL, Zhang CP, Nie F, Xu XT, Zhu MM,
Xiao SD and Ran ZH: MicroRNA 506 regulates expression of PPAR alpha
in hydroxycamptothecin-resistant human colon cancer cells. FEBS
Lett. 585:3560–3568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shalaby T, Fiaschetti G, Baumgartner M and
Grotzer MA: Significance and therapeutic value of miRNAs in
embryonal neural tumors. Molecules. 19:5821–5862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhi F, Wang R, Wang Q, Xue L, Deng D, Wang
S and Yang Y: MicroRNAs in neuroblastoma: Small-sized players with
a large impact. Neurochem Res. 39:613–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mei H, Lin ZY and Tong QS: The roles of
microRNAs in neuroblastoma. World J Pediatr. 10:10–16. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Domingo-Fernandez R, Watters K, Piskareva
O, Stallings RL and Bray I: The role of genetic and epigenetic
alterations in neuroblastoma disease pathogenesis. Pediatr Surg
Int. 29:101–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Verissimo CS, Molenaar JJ, Fitzsimons CP
and Vreugdenhil E: Neuroblastoma therapy: What is in the pipeline?
Endocr Relat Cancer. 18:R213–R231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stallings RL, Foley NH, Bray IM, Das S and
Buckley PG: MicroRNA and DNA methylation alterations mediating
retinoic acid induced neuroblastoma cell differentiation. Semin
Cancer Biol. 21:283–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak and Schmittgen, . Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R,
Zhang W, Lv Z, Zheng S and Zhou L: NDRG1 as a biomarker for
metastasis, recurrence and of poor prognosis in hepatocellular
carcinoma. Cancer Lett. 310:35–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Almeida MI, Reis RM and Calin GA:
MicroRNAs and metastases - the neuroblastoma link. Cancer Biol
Ther. 9:453–454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schulte JH, Horn S, Schlierf S, Schramm A,
Heukamp LC, Christiansen H, Buettner R, Berwanger B and Eggert A:
MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett.
274:10–15. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stallings RL: MicroRNA involvement in the
pathogenesis of neuroblastoma: Potential for microRNA mediated
therapeutics. Curr Pharm Des. 15:456–462. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y,
Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K,
et al: MiR-506 inhibits multiple targets in the
epithelial-to-mesenchymal transition network and is associated with
good prognosis in epithelial ovarian cancer. J Pathol. 235:25–36.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koutsaki M, Spandidos DA and Zaravinos A:
Epithelial-mesenchymal transition-associated miRNAs in ovarian
carcinoma, with highlight on the miR-200 family: Prognostic value
and prospective role in ovarian cancer therapeutics. Cancer Lett.
351:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot
CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang
D, Kerrigan BC Parker, Shmulevich I, Chen K, Sood AK, et al:
MiR-506 suppresses proliferation and induces senescence by directly
targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol.
233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Cui M, Sun BD, Liu FB, Zhang XD
and Ye LH: MiR-506 suppresses proliferation of hepatoma cells
through targeting YAP mRNA 3′UTR. Acta Pharmacol Sin. 35:1207–1214.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R,
Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, et al: miR-506 acts as a
tumor suppressor by directly targeting the hedgehog pathway
transcription factor Gli3 in human cervical cancer. Oncogene.
34:717–725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao Z, Ma X, Hsiao TH, Lin G, Kosti A, Yu
X, Suresh U, Chen Y, Tomlinson GE, Pertsemlidis A and Du L: A
high-content morphological screen identifies novel microRNAs that
regulate neuroblastoma cell differentiation. Oncotarget.
5:2499–2512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin M, Ren X, Zhang X, Luo Y, Wang G,
Huang K, Feng S, Bao X, Huang K, He X, et al: Selective killing of
lung cancer cells by miRNA-506 molecule through inhibiting NF-κB
p65 to evoke reactive oxygen species generation and p53 activation.
Oncogene. 34:691–703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arora H, Qureshi R and Park WY: miR-506
regulates epithelial mesenchymal transition in breast cancer cell
lines. PLoS One. 8:e642732013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nunes KP, Rigsby CS and Webb RC:
RhoA/Rho-kinase and vascular diseases: What is the link? Cell Mol
Life Sci. 67:3823–3836. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schofield AV and Bernard O: Rho-associated
coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem
Mol Biol. 48:301–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li HP, Huang HY, Lai YR, Huang JX, Chang
KP, Hsueh C and Chang YS: Silencing of miRNA-148a by
hypermethylation activates the integrin-mediated signaling pathway
in nasopharyngeal carcinoma. Oncotarget. 5:7610–7624. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cai H, Lin L, Cai H, Tang M and Wang Z:
Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor
progression and prognosis in pediatric osteosarcoma. Int J Mol Sci.
15:560–573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC,
Lee JH, Lee SS, Ashktorab H, Smoot DT, Ryu KW, et al: MicroRNA 135a
suppresses lymph node metastasis through down-regulation of ROCK1
in early gastric cancer. PLoS One. 9:e852052014. View Article : Google Scholar : PubMed/NCBI
|
